Hostname: page-component-745bb68f8f-lrblm Total loading time: 0 Render date: 2025-01-24T05:46:18.573Z Has data issue: false hasContentIssue false
  • English
  • Français

Optimum Symptomatic Control of Parkinson's Disease with Dopaminergic Therapy

Published online by Cambridge University Press:  05 January 2016

Sylvie Bouchard
Sylvie Bouchard*
Affiliation:
Division of Central Nervous System, Clinical Research Department, SANDOZ Pharmaceuticals, Montreal
*
Laboratoires SANDOZ S.A.R.L., 14. Boulevard Richelieu, 92506 Rueil Malmaison Cedex, France
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

This paper presents a review of the literature on the therapeutic action and the side effects of the two main dopaminergic agents: L-DOPA/decarboxylase inhibitor (L-DOPA/DI) and bromocriptine (Parlodel ®) used either as monotherapy or in combination in patients with Parkinson's disease. The combination of L-DOPA/DI and bromocriptine gives the best therapeutic efficacy (49% improvement) in the total score (bradykinesia, rigidity and tremor). However, treatment by monotherapy or combination gives the same pattern of activity: greatest improvement in tremor, followed by rigidity and bradykinesia. Improvement observed in the short term is not sustained over longer periods of time for monotherapy with either drug. The short-term side effects are similar for each treatment, whereas long-term complications (dyskinesia, end-of-dose deterioration and on-off phenomenon) appear only when levodopa is used, alone (high incidence) or in combination with bromocriptine (low incidence). The overall optimum treatment is obtained with a combination of L-DOPA/DI and bromocriptine.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 14 , Issue S3 , August 1987 , pp. 460 - 465
Copyright
Copyright © Canadian Neurological Sciences Federation 1987

References

REFERENCES

1.Ehringer, H, Hornykiewicz, O.Distribution of noradrenaline and dopamine (3-hydroxytyramine) in human brain: their behaviour in extrapyramidal system diseases. Klin Wschr 1960; 38: 1236–1239.CrossRefGoogle Scholar
2.Barbeau, A, Murphy, GF, Sourkes, TL. Low dopamine concentra-tions in urine of patients with Parkinson’s disease. Science 1961 ; 133: 1706–1707.CrossRefGoogle Scholar
3.Barbeau, A.Biochemistry of Parkinson’ disease. Excerpta Med-ica ICS 1961:38: 152–153.Google Scholar
4.Birkmayer, W, Hornykiewicz, O.DerL-3,4-dioxyphenylalanin(Dopa)- Effekt bei der Parkinson akinese. Wien Klin Wschr 1961; 73: 787–795.Google Scholar
5.Cotzias, GC. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276: 374–379.CrossRefGoogle ScholarPubMed
6.Yahr, MD.Levodopa. Ann Intern Med 1975; 83: 677–682.CrossRefGoogle ScholarPubMed
7.Boshes, B.Sinemet and the treatment of parkinsonism. Ann Intern Med 1981; 94: 364–370.CrossRefGoogle ScholarPubMed
8.Marsden, CD and Parkes, JD. “On-off” effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet 1976: 1: 292–296.CrossRefGoogle ScholarPubMed
9.Yahr, MD. Limitations of long term use of antiparkinson drugs. Can J Neurol Sci 1984; 2: 191–194.CrossRefGoogle Scholar
10.Kartzinel, R, Teychenne, P.Gillespie, MM, et al. Bromocriptine and levodopa (with or without carbidopa) in parkinsonism. Lancet 1976: 272–275.CrossRefGoogle Scholar
11.Calne, DB. Dopaminergic agonists in the treatment of parkinsonism. Clin Neuropharmacol 1978; 3: 153–166.CrossRefGoogle Scholar
12.Calne, DB, Burton, K, Beckman, U, Martin, WRW. Dopamine ago- nists in Parkinson’s disease. Can J Neurol Sci 1984; 11:221–224.CrossRefGoogle Scholar
13.Calne, DB, Teychenne, PF, Claveria, LE, et al. Bromocriptine in parkinsonism. Br Med J 1974; 4: 442–444.CrossRefGoogle ScholarPubMed
14.Rinne, UK. New ergot derivatives in the treatment of Parkinson’s disease. In: Calne, DB, McDonald, RJ, Horowski, R, Writtke, W, eds. Lisuride and other dopamine agonists. New York: Raven Press. 1983: 431–442.Google Scholar
15.Lang, AE, Sheeby, MP, Quinn, NP, et al. Lisuride and pergolide in Parkinson’s disease. In: Fahn, S, Calne, DB, Shoulson, I, eds. Advances in Neurology. Vol 37. Experimental therapeutics of movement disorders. New York: Raven Press, 1983: 109–120.Google Scholar
16.Mear, JY, Barroche, G, de Smet, Y, et al. Pergolide in the treatment of Parkinson’s disease. Neurology 1984; 34: 983–986.CrossRefGoogle ScholarPubMed
17.Kurlan, R, Miller, C, Levy, R.et al. Long term experience with pergolide therapy of advanced parkinsonism. Neurology 1985; 35: 738–742.CrossRefGoogle ScholarPubMed
18.Teràvàinen, H, Huttunen, J, Hietanen, M.Initial treatment of parkin- sonism with 8-alpha-amino-ergoline. Neurology 1985; 35: 83–87.CrossRefGoogle Scholar
19.Diamond, SG and Markham, CH.Evaluating the evaluations: or how to weigh the scales of parkinsonian disability. Neurology (Cleveland) 1983; 33: 1098–1099.CrossRefGoogle ScholarPubMed
20.Hoehn, MM, Yahr, MD.Parkinsonism: onset, progression and mortality. Neurology (Minneap) 1967; 17: 427–442.CrossRefGoogle ScholarPubMed
21.Rinne, UK.Combined bromocriptine-Ievodopa therapy early in Parkinson’s disease. Neurology 1985; 35: 1196–1198.CrossRefGoogle ScholarPubMed
22.Agid, Y.In: Calne, DB, Fahn, S, Goldstein, H, Marsden, D, eds. Parkinson’s disease, New York, McMillan, 1987; in press.Google Scholar
23.Fahn, S and Bressman, SB.Should levodopa therapy for parkinson-ism be started early or late? Evidence against early treatment. Can J Neurol Sc 1984; 11: 200–205.CrossRefGoogle ScholarPubMed
24.Lee, T, Seeman, P, Rajput, A, et al. Receptor basis for dopaminergic supersensitivity in Parkinson’s disease. Nature 1978; 273:897–900.CrossRefGoogle ScholarPubMed
25.Sweet, RD, Lee, JE, Spiegel, HD, McDowell, F.Exhausted response to low doses of levodopa after withdrawal from chronic treatment. Neurology 1972; 22: 520–525.CrossRefGoogle Scholar
26.Hunter, KR, Shaw, KM, Laurence, DR, Stern, GM. Sustained levodopa therapy in parkinsonism. Lancet 1973; 2: 929–931.CrossRefGoogle ScholarPubMed
27.Marsden, CD and Parkes, JD.Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet 1977; 1:345–349.CrossRefGoogle ScholarPubMed
28.Barbeau, A.High-level levodopa therapy in severely akinetic par-kinsonian patients: twelve years later. In: Rinne, UK, Klinger, M, Stamm, G, eds. Parkinson’s disease - current progress, problems and management. North Holland Biomedical Press, Elsevier 1980: 229–239.Google Scholar
29.Lees, AJ, Haddad, S, Shaw, KM.Bromocriptine in parkinsonism. Arch Neurol 1978; 35: 503–505.CrossRefGoogle ScholarPubMed
30.Lees, AJ, Stern, GM.Sustained bromocriptine therapy in previously untreated patients with Parkinson’ disease. J Neurol Neurosurg Psychiatry 1981; 43: 1020–1023.CrossRefGoogle Scholar
31.Lieberman, A, Kupersmith, M, Neophytides, A.Long term efficacy of bromocriptine in Parkinson’s disease. Neurology 1980; 30: 518–523.CrossRefGoogle Scholar
32.Goetz, CG, Tanner, CM, Glantz, RH, Klawans, HL.Chronic agonist therapy for Parkinson’s disease: a 5-year study of bromocriptine and pergolide. Neurology 1985; 35: 749–751.CrossRefGoogle ScholarPubMed
33.Rascol, A, Guiraud, B, Montastruc, JL, et al. Long-term treatment of Parkinson’s disease with bromocriptine. J Neurol Neurosurg Psychiatry 1979; 42: 143–150.CrossRefGoogle ScholarPubMed
34.Goldstein, M, Lieberman, A.Meller, E.A possible molecular mecha-nism for the antiparkinsonian action of bromocriptine in combination with levodopa. Trends Pharmacol Sci 1985; 6: 436–437.Google Scholar
35.Caraceni, T., Giovannini, P, Girotti, F.et al. Long-term evaluation of combined treatment of Parkinson’s disease with L-Dopa, peripheral decarboxylase inhibitors and bromocriptine, ltal J Neurol Sci 1981; 2: 337–342.Google Scholar
36.Rascol, A, Montastruc, JL, Guiraud-Chaumeil, B.Clavet, M.La bromocriptine comme premier traitement de la maladie de Parkinson. Rev Neurol (Paris) 1982; 138: 401–408.Google Scholar
37.Teychenne, PF.Parkinson’s disease: the current status of drug treatment: the role of peptides. Neurotransmitters and Neuropeptides, 1983: 19–33.Google Scholar
38.Rajput, AH, Stern, W, Laverty, WH. Chronic low-dose levodopa therapy in Parkinson’s disease: an argument for delaying levodopa therapy. Neurology 1984; 34: 991–996.CrossRefGoogle ScholarPubMed
39.Markham, CH and Diamond, SG.Long-term follow-up of early dopa treatment in Parkinson’s disease. Ann Neurol 1986; 19: 365–372.CrossRefGoogle ScholarPubMed
40.Agid, Y, Bonnet, AM, Pollak, P, et al. Bromocriptine associated with a peripheral dopamine blockingagent in treatment of Parkinson’s disease. Lancet 1979; 1: 570–572.CrossRefGoogle Scholar
41.Lieberman, A, Kupersmith, M, Estey, E, Goldstein, M.Treatment of Parkinson’s disease with bromocriptine. New Engl J Med 1976: 295: 1400–1404.CrossRefGoogle ScholarPubMed
42.Rosengarten, H.Schweitzer, JW, Friedhoff, AJ.Induction of oral dyskinesias in naive rats by DI stimulation. Life Sciences 1983; 33: 2479–2482.CrossRefGoogle Scholar
43.Bedard, PJ, Di Paolo, T, Falardeau, P, Boucher, R.Chronic treatment with levodopa. but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with (3H) spiperone binding. Brain Res 1986: 379: 294.CrossRefGoogle Scholar
44.Lees, AJ and Stern, GM.Sustained low dose levodopa therapy in Parkinson’s disease. A 3-year follow-up. Adv Neurol 1983; 37: 9–15.Google ScholarPubMed
45.McDowell, FH and Sweet, RD.The “on-off” phenomenon. In: Birkmayer, W and Hornykiewicz, O, eds. Advances in parkinsonism. Basle: ed. Roche 1976: 603–612.Google Scholar
46.Markham, CH and Diamond, SG.Evidence to support early levodopa therapy in Parkinson’s disease. Neurology 1981 ; 31: 125–131.CrossRefGoogle Scholar
47.Rinne, UK.Dopamine agonists as primary treatment in parkinson’s disease. In: Yahr, MD, Bergmann, KJ, eds. Adv Neurol New York: Raven Press 1986; 45: 519–523.Google Scholar
48.Olanow, CW and Alberts, MJ.Low-dose bromocriptine in pre-viously untreated Parkinson patients. In: Fahn, S.Marsden, CD, Jenner, P.Teychenne, P. eds. Recent developments in Parkinson’s disease. New York: Raven Press, 1986: 273–278.Google Scholar
49.Devathasan, G.Chong, PN.Prevanendran, K, et al. Low-dose bromocriptine therapy in severe Parkinson’s disease. Clin Neuropharmacol 1984: 7: 231–237.CrossRefGoogle ScholarPubMed
50.Grimes, JD and Delgado, MR.Bromocriptine: problems with low-dose de novo therapy in Parkinson’s disease. Clin Neuropharmacol 1986; 8: 73–77.CrossRefGoogle Scholar
51.Rinne, UK and Marttila, R.Brain dopamine receptor stimulation and the relief of parkinsonism: relationship between bromocriptine and levodopa. Ann Neurol 1978; 4: 263–267.CrossRefGoogle ScholarPubMed
52.Riopelle, RJ, Gawel, M, Libman, I, et al. A double-blind study of bromocriptine and L-Dopa in de novo Parkinson’s disease -“Short-term” results. In: Calne, DB.Fahn, S, Goldstein, M.Marsden, CD, eds. Parkinson’s disease. New York. McMillan, 1987; in press.Google ScholarPubMed
53.Staal-Schreinemachers, AL, Wesseling, H, Kamphuis, DJ.et al. Low-dose bromocriptine therapy in Parkinson’s disease: double-blind, placebo-controlled study. Neurol 1986; 36: 291–293.CrossRefGoogle ScholarPubMed
54.Teychenne, PF, Bergsrud, D, Elton, RL.Racy, A.Bromocriptine: long-term low-dose therapy in Parkinson’s disease. Clin Neuropharmacol 1986; 9: 138–145.CrossRefGoogle ScholarPubMed
55.Caraceni, TA, Celano, I, Parati, E.Girotti, F.Bromocriptine alone or associated with L-Dopa plus benzerazide in Parkinson’s disease. J Neurol Neurosurg and Psychiat 1977; 40: 1142–1146.CrossRefGoogle ScholarPubMed
56.Jansen, ENH. Bromocriptine in levodopa response-losing parkin-sonism. Europ Neurol 1978; 17: 92–99.CrossRefGoogle Scholar
57.Jellinger, K.Adjuvant treatment of Parkinson’s disease with dopa- mine agonists: open trial with bromocriptine and CU 32-085. J Neurol 1982; 227: 75–88.CrossRefGoogle Scholar
58.Sweet, RD and McDowell, FH.Five years’ treatment of Parkinson’s disease with levodopa. Ann lnt Med 1975: 83: 456–463.CrossRefGoogle ScholarPubMed
59.Yahr, MD.Evaluation of long-term therapy in Parkinson’s disease: mortality and therapeutic efficacy. In: Birkmayer, W and Hornykiewicz, O. eds. Advances in Parkinsonism. Basle: ed. Roche, 1976: 435–443.Google Scholar